Sign up to receive our newsletter

 

OTTBD News

04/1/13
BioMarin Submits CTA for BMN-190 for Batten Disease
Full Press Release

03/31/13
Dr. Scott Kachlany of the New Jersey Dental School at UMDNJ is featured in myCentralJersey.com -- New drug in development shows promise for treatment of leukemia, lymphoma and 80 autoimmune diseases
Full Article

01/25/13
Foundation Venture Capital Group Invests In Start-Up Working to Reduce Side Effects of Parkinson’s Treatment
Full Press Release

01/23/13
A Healthy Venture in New Jersey
New Jersey Health Foundation and the University of Medicine and Dentistry of New Jersey collaborate on new venture model to commercialise university IPs.
Full Article

 

OTTBD Events

4/23/13
The NJTC and Rutgers University present an Entrepreneur Bootcamp - an opportunity for seed and early stage entrepreneurs to talk and network with advisors and thought leaders.
For more information click here

6/6/13
Call for Presentations at BioNJ Personalized Medicine innovation Summit.
For more information click here

News

04/1/13
PRESS RELEASE

BioMarin Submits CTA for BMN-190 for Batten Disease
SAN RAFAEL, Calif., April 1, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that it has submitted a Clinical Trial Application (CTA) with the Medicines and Healthcare Products Regulatory Agency (MHRA) in the U.K. for BMN-190, a recombinant human tripeptidyl peptidase 1 (rhTPP1) for the treatment of patients with neuronal ceroid lipofuscinosis type 2 (NCL-2), a form of Batten disease. The company expects to start enrolling patients in a Phase 1/2 trial in mid-2013.

Click here for full press release

 

03/31/13
Dr. Scott Kachlany of the New Jersey Dental School at UMDNJ is featured in myCentralJersey.com -- New drug in development shows promise for treatment of leukemia, lymphoma and 80 autoimmune diseases

Full article

 

01/25/13

For Immediate Release January 25, 2013  Contact: Dale R. Heffler (908) 731-6605 dheffler@njhf.org

Foundation Venture Capital Group Invests In Start-Up Working to Reduce Side Effects of Parkinson’s Treatment

New Brunswick, NJ—Parkinson’s disease affects one million people in the United States and seven million worldwide. While L-Dopa is effective in treating the disease symptoms, the vast majority of patients taking it chronically eventually develop L-Dopa Induced Dyskinesia (LID), abnormal involuntary movements that can be disabling.

A new company, MentiNova, Inc., is exploring an oral medication that could reduce these uncontrollable, often chaotic movements in patients being treated with L-Dopa. Foundation Venture Capital Group (FVCG), an affiliate of New Jersey Health Foundation, has committed up to $500,000 to advance this research and development.
Full Press Release

 

01/23/13

A Healthy Venture in New Jersey

New Jersey Health Foundation and the University of Medicine and Dentistry of New Jersey collaborate on new venture model to commercialise university IPs.

Author: Tim Lafferty, Managing Director, Global University Venturing
New Jersey Health Foundation and the University of Medicine and Dentistry of New Jersey (UMDNJ) have developed a rare venture model to foster the commercialisation of university intellectual property (IP). 
Full Article